Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 20.99% is 33% above its 5-year average of 15.80%, around the middle of its 5-year range (-15.35%–48.71%).
As of the fiscal period ended Tuesday, June 30, 2026. 1.25% above its 12-month average of 20.73%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): 20.99%.
RETURN ON EQUITY (ROE)
20.99%
RETURN ON EQUITY (ROE) AVG TTM
20.73%
RETURN ON EQUITY (ROE) AVG 3Y
26.30%
RETURN ON EQUITY (ROE) AVG 5Y
15.80%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+1.25%
CURRENT VS 3Y AVG
-20.19%
CURRENT VS 5Y AVG
+32.84%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-40.21%
median of 605 covered companies
CURRENT VS SECTOR MEDIAN
+152.19%
vs the sector median at left
Lantheus Holdings, Inc.
Market Cap
$6.51B
Return on Equity (ROE)
20.99%
TTM Avg
20.73%
3Y Avg
26.30%
5Y Avg
15.80%
Market Cap
$6.56B
Return on Equity (ROE)
476.51%
TTM Avg
2.59%
3Y Avg
-115.75%
5Y Avg
-71.67%
Market Cap
$6.59B
Return on Equity (ROE)
-43.83%
TTM Avg
25.09%
3Y Avg
5.57%
5Y Avg
0.40%
Market Cap
$6.67B
Return on Equity (ROE)
33.11%
TTM Avg
27.03%
3Y Avg
27.48%
5Y Avg
31.41%
Market Cap
$6.74B
Return on Equity (ROE)
-73.19%
TTM Avg
-58.90%
3Y Avg
-54.50%
5Y Avg
-46.46%
Market Cap
$6.02B
Return on Equity (ROE)
20.38%
TTM Avg
5.87%
3Y Avg
3.40%
5Y Avg
3.36%
Market Cap
$6.00B
Return on Equity (ROE)
-15.40%
TTM Avg
-48.41%
3Y Avg
-63.30%
5Y Avg
-53.67%
Market Cap
$5.95B
Return on Equity (ROE)
-39.33%
TTM Avg
-54.18%
3Y Avg
-65.89%
5Y Avg
-59.69%
Market Cap
$7.14B
Return on Equity (ROE)
3.66%
TTM Avg
19.17%
3Y Avg
13.19%
5Y Avg
6.34%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lantheus Holdings, Inc. (LNTH) | $6.51B | 20.99% | 20.73% | 26.30% | 15.80% |
| Amneal Pharmaceuticals, Inc. (AMRX)vs › | $6.56B | 476.51% | 2.59% | -115.75% | -71.67% |
| Hims & Hers Health, Inc. (HIMS)vs › | $6.59B | -43.83% | 25.09% | 5.57% | 0.40% |
| Chemed Corporation (CHE)vs › | $6.67B | 33.11% | 27.03% | 27.48% | 31.41% |
| Immunovant, Inc. (IMVT)vs › | $6.74B | -73.19% | -58.90% | -54.50% | -46.46% |
| Ligand Pharmaceuticals Incorporated (LGND)vs › | $6.02B | 20.38% | 5.87% | 3.40% | 3.36% |
| GRAIL Inc. (GRAL)vs › | $6.00B | -15.40% | -48.41% | -63.30% | -53.67% |
| Iovance Biotherapeutics, Inc. (IOVA)vs › | $5.95B | -39.33% | -54.18% | -65.89% | -59.69% |
| Alkermes plc (ALKS)vs › | $7.14B | 3.66% | 19.17% | 13.19% | 6.34% |
| CG Oncology Inc. (CGON)vs › | $5.87B | -21.80% | -16.70% | -22.00% | -23.98% |
ROE
21.0%
ROA
11.4%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | 20.99% |
| 2026-03-31 | 23.02% |
| 2025-12-31 | 21.43% |
| 2025-09-30 | 14.98% |
| 2025-06-30 | 23.23% |
| 2025-03-31 | 21.85% |
| 2024-12-31 | 28.72% |
| 2024-09-30 | 36.25% |
| 2024-06-30 | 41.73% |
| 2024-03-31 | 48.71% |
| 2023-12-31 | 40.04% |
| 2023-09-30 | 14.90% |
| 2023-06-30 | 6.04% |
| 2023-03-31 | -3.97% |
| 2022-12-31 | 6.28% |
| 2022-09-30 | 16.78% |
| 2022-06-30 | 5.71% |
| 2022-03-31 | -7.24% |
| 2021-12-31 | -15.35% |
| 2021-09-30 | -6.90% |
| 2021-06-30 | -5.40% |
| 2021-03-31 | -1.48% |
| 2020-12-31 | -2.62% |
| 2020-09-30 | 0.08% |
| 2020-06-30 | 2.26% |
| 2020-03-31 | 21.16% |
| 2019-12-31 | 27.63% |
| 2019-09-30 | 34.11% |
| 2019-06-30 | 42.19% |
| 2019-03-31 | 50.78% |
| 2018-12-31 | 57.07% |
| 2018-09-30 | 224.02% |
| 2018-06-30 | 277.56% |
| 2018-03-31 | 378.62% |
| 2017-12-31 | 529.75% |
